New Drug Product: Breztri Aerosphere
This slideshow shows drug information for Breztri Aerosphere. Click here for the complete Breztri Aerosphere monograph.
Chronic Obstructive Pulmonary Disease
Pulmonary Hypertension May Increase In-Hospital Mortality in Acute COPD Exacerbations
Pulmonary hypertension is associated with higher in-hospital mortality, morbidity, length of stay, and health care utilization in patients admitted to the hospital with an acute exacerbation of COPD.
COVID-19 With COPD: Fewer Hospitalizations, But Greater Mortality
Chronic obstructive pulmonary disease may be associated with higher rates of mortality in patients with coronavirus disease 2019.
Secondary Spontaneous Pneumothorax Incidence in COPD, Emphysema
The incidence and prevalence of a first-ever spontaneous pneumothorax in patients with chronic obstructive pulmonary disease (COPD) and emphysema are increased significantly in men and in Black patients.
ATS: Clinical Practice Guidelines on the Pharmacologic Management of COPD
The American Thoracic Society has released a new clinical practice guideline on the pharmacologic management of chronic obstructive pulmonary disease.
Antiplatelet Therapy in COPD May Reduce All-Cause Mortality, Improve QoL
Antiplatelet therapy may delay progression of COPD, decrease the risk for acute exacerbations, improve quality of life, and even reduce all-cause mortality.
Oral Sustained-Release Morphine May Improve Moderate, Severe Breathlessness in COPD
The use of regular, low-dose, oral sustained-release morphine for 4 weeks in patients with COPD and moderate to very severe breathlessness has been shown to improve disease-specific health status.
Dupilumab Improves Lung Function in CRSwNP and Comorbid Asthma and COPD Features
Treatment with dupilumab led to significant improvements in lung function by 16 weeks and up to 24 weeks in patients with chronic rhinosinusitis with nasal polyps and comorbid asthma plus clinical features of COPD.
Triple Combination Therapy Improves Long-Term Lung Function in COPD
Patients with COPD who received a metered dose inhaler containing budesonide, glycopyrrolate, and formoterol fumarate showed lung function improvements through 52 weeks.
First-in-Class Dual PDE Inhibitor Plus Tiotropium May Improve Lung Function in COPD
Nebulized ensifentrine, when added to tiotropium, produced clinically meaningful and significant improvements in lung function and quality of life in patients with COPD.
